Drug intelligence / Profile preview

RJ010

Development stage: Preclinical
Lead developer: Risen
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RJ010 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Risen Shanghai Medical Technology (Risen Pharma) for the treatment of autoimmune diseases. As an siRNA molecule, RJ010 is designed to silence the expression of a specific, currently undisclosed, pathogenic gene involved in the inflammatory or immune response pathways. The drug is part of Risen Pharma's broader RNA therapeutics platform, which focuses on leveraging RNA interference (RNAi) to address unmet medical needs in immunology and metabolic diseases.

Beyond the preview

Go deeper on RJ010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ010.

Explore the full profile